FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 124 filers reported holding FIVE PRIME THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $103,161,000 | +63.3% | 26,622 | +154.1% | 0.00% | – |
| Q2 2019 | $63,171,000 | -68.5% | 10,476 | -30.0% | 0.00% | – |
| Q1 2019 | $200,411,000 | -88.0% | 14,956 | -84.6% | 0.00% | -100.0% |
| Q1 2018 | $1,664,020,000 | -21.6% | 96,858 | 0.0% | 0.00% | -50.0% |
| Q4 2017 | $2,123,127,000 | -51.8% | 96,858 | -10.1% | 0.00% | -50.0% |
| Q3 2017 | $4,405,597,000 | +43.3% | 107,690 | +5.5% | 0.00% | +33.3% |
| Q2 2017 | $3,073,929,000 | -30.4% | 102,090 | -16.5% | 0.00% | -40.0% |
| Q1 2017 | $4,418,252,000 | +56305.6% | 122,220 | -21.8% | 0.01% | -44.4% |
| Q4 2016 | $7,833,000 | +455.1% | 156,301 | +481.1% | 0.01% | +350.0% |
| Q3 2016 | $1,411,000 | +43.8% | 26,897 | +13.4% | 0.00% | +100.0% |
| Q2 2016 | $981,000 | +5.6% | 23,721 | +3.7% | 0.00% | 0.0% |
| Q1 2016 | $929,000 | -20.9% | 22,870 | -19.2% | 0.00% | 0.0% |
| Q4 2015 | $1,174,000 | +393.3% | 28,302 | +194.8% | 0.00% | – |
| Q2 2015 | $238,000 | – | 9,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 115,500 | $2,531,000 | 0.89% |
| AWM Investment Company, Inc. | 150,000 | $3,288,000 | 0.64% |
| BB BIOTECH AG | 827,500 | $18,139,000 | 0.51% |
| Virtus ETF Advisers LLC | 17,371 | $381,000 | 0.48% |
| Rock Springs Capital Management LP | 425,000 | $9,316,000 | 0.42% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,728 | $9,880,000 | 0.39% |
| Telemetry Investments, L.L.C. | 44,176 | $968,000 | 0.37% |
| RTW INVESTMENTS, LP | 100,377 | $2,200,000 | 0.37% |
| Eventide Asset Management | 315,000 | $6,905,000 | 0.36% |
| ACUTA CAPITAL PARTNERS, LLC | 52,500 | $1,151,000 | 0.22% |